Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
For Surrozen, Inc. (SRZN), AI Biotechnology LLC reported beneficial ownership of 2,212,556 shares, or 9.9% of the common stock. The reported amount includes 1,021,043 shares held directly, including 252,605 acquired in the November 2026 offering, and 1,191,513 shares issuable under warrants treated as beneficially owned. Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik reported the same shared voting and dispositive power figures, while disclaiming beneficial ownership.
AI Biotechnology holds pre-funded warrants for 754,500 shares exercisable at $0.0001 per share and Series E warrants for 757,500 shares exercisable at $11.54 per share. The blocker excludes 320,487 warrant shares from the reported amount. Warrants may not be exercised if doing so would raise beneficial ownership above 9.99%; the limit may be changed by notice effective on the 61st day, subject to a 19.99% maximum.
Key Figures
Beneficial ownership:2,212,556 sharesReported ownership percentage:9.9%Shares held directly:1,021,043 shares+5 more
8 metrics
Beneficial ownership2,212,556 sharesReported by AI Biotechnology LLC and the related reporting persons
Reported ownership percentage9.9%Based on the denominator described in the ownership report
Shares held directly1,021,043 sharesHeld directly by AI Biotechnology LLC
Pre-funded warrant shares754,500 sharesExercisable at $0.0001 per share
Series E warrant shares757,500 sharesExercisable at $11.54 per share
Warrant shares treated as beneficially owned1,191,513 sharesAfter applying the Beneficial Ownership Blocker
Warrant shares excluded320,487 sharesExcluded due to the Beneficial Ownership Blocker
Beneficial-ownership limit9.99%Warrants may not be exercised if the limit would be exceeded
Key Terms
Beneficial Ownership Blocker, Pre-funded Warrants, Series E Warrants, Rule 13d-3
4 terms
Beneficial Ownership Blockerregulatory
"the Beneficial Ownership Blocker"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
Pre-funded Warrantstechnical
"Pre-funded Warrants exercisable at any time"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Series E Warrantstechnical
"Series E Warrants exercisable at any time"
Rule 13d-3regulatory
"as calculated under Rule 13d-3"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Surrozen (SRZN) shares does AI Biotechnology report owning?
AI Biotechnology reports beneficial ownership of 2,212,556 shares, or 9.9% of Surrozen's common stock. The amount includes 1,021,043 shares held directly and 1,191,513 shares issuable under warrants treated as beneficially owned.
What is the warrant exercise limit for Surrozen (SRZN) shares?
The warrants may not be exercised above a 9.99% ownership limit if the exercise would cause AI Biotechnology and its affiliates to exceed that level. AI Biotechnology may change the limit by notice to Surrozen, effective on the 61st day after delivery, but may not raise it above 19.99%.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Surrozen, Inc.
(Name of Issuer)
Common stock, par value $0.0001 per share
(Title of Class of Securities)
86889P208
(CUSIP Number)
11/16/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
86889P208
1
Names of Reporting Persons
AI Biotechnology LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,212,556.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,212,556.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,212,556.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Rows 6, 8 and 9: The total number of shares of common stock, par value $0.0001 per share (the "Common Stock"), of Surrozen, Inc. (the "Issuer") reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology LLC ("AI Biotechnology") and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker (as defined in Item 4), but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker.
Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in its November 2026 underwritten public offering (the "Offering"), as reported in the Issuer's Current Report on Form 8-K filed with the SEC on November 16, 2026, and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.
SCHEDULE 13G
CUSIP Number(s):
86889P208
1
Names of Reporting Persons
Access Industries Holdings LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,212,556.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,212,556.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,212,556.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Rows 6, 8 and 9: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker, but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker.
Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.
SCHEDULE 13G
CUSIP Number(s):
86889P208
1
Names of Reporting Persons
Access Industries Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,212,556.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,212,556.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,212,556.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Rows 6, 8 and 9: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker, but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker.
Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.
SCHEDULE 13G
CUSIP Number(s):
86889P208
1
Names of Reporting Persons
Len Blavatnik
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,212,556.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,212,556.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,212,556.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Rows 6, 8 and 9: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker, but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker.
Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Surrozen, Inc.
(b)
Address of issuer's principal executive offices:
171 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080
Item 2.
(a)
Name of person filing:
AI Biotechnology LLC
Access Industries Holdings LLC ("AIH")
Access Industries Management, LLC ("AIM")
Len Blavatnik
(b)
Address or principal business office or, if none, residence:
The principal business office of each reporting person is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.
(c)
Citizenship:
Each of AI Biotechnology, AIH and AIM is a limited liability company organized under the laws of the State of Delaware.
Mr. Blavatnik is a citizen of the United States of America.
(d)
Title of class of securities:
Common stock, par value $0.0001 per share
(e)
CUSIP No.:
86889P208
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See the responses to Item 9 on the attached cover pages.
(b)
Percent of class:
See the responses to Item 11 of the attached cover pages. The percentages reported in Item 11 of the attached cover pages are based upon the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See the responses to Item 5 on the attached cover pages.
(ii) Shared power to vote or to direct the vote:
See the responses to Item 6 on the attached cover pages.
(iii) Sole power to dispose or to direct the disposition of:
See the responses to Item 7 on the attached cover pages.
(iv) Shared power to dispose or to direct the disposition of:
See the responses to Item 8 on the attached cover pages.
AI Biotechnology (a) directly holds 1,021,043 shares of Common Stock, including 252,605 shares acquired in the Offering, and (b) directly holds (i) Pre-funded Warrants exercisable at any time at a price per share of $0.0001 for an aggregate of 754,500 shares of Common Stock and (ii) Series E Warrants exercisable at any time at an exercise price of $11.54 for an aggregate of 757,500 shares of Common Stock, of which an aggregate of 1,191,513 shares of Common Stock are treated as beneficially owned after giving effect to the Beneficial Ownership Blocker (defined below).
The Pre-funded Warrants and the Series E Warrants held directly, or that may be acquired within 60 days of this filing, by AI Biotechnology may not be exercised if the aggregate number of shares of Common Stock beneficially owned by AI Biotechnology (together with its affiliates) immediately following such exercise would exceed 9.99% of the outstanding shares of Common Stock, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AI Biotechnology may increase or decrease the foregoing beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (the "Beneficial Ownership Blocker").
The shares of Common Stock that may be deemed to be beneficially owned as of the date of this filing by AI Biotechnology may also be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, (ii) AIM controls AIH, and (iii) AIH directly controls all of the outstanding voting interests in in AI Biotechnology. Each of the Reporting Persons (other than AI Biotechnology) and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
AI Biotechnology LLC
Signature:
/s/ Alejandro Moreno
Name/Title:
By: Access Industries Management, LLC, its manager; its Executive Vice President/Alejandro Moreno
Date:
11/20/2026
Access Industries Holdings LLC
Signature:
/s/ Alejandro Moreno
Name/Title:
By: Access Industries Management, LLC, its manager; its Executive Vice President/Alejandro Moreno
Date:
11/20/2026
Access Industries Management, LLC
Signature:
/s/ Alejandro Moreno
Name/Title:
Executive Vice President/Alejandro Moreno
Date:
11/20/2026
Len Blavatnik
Signature:
*/s/Alejandro Moreno
Name/Title:
By: Alejandro Moreno/Attorney-in-Fact
Date:
11/20/2026
Comments accompanying signature: * The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.